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PPRECLINICAL STUDY
Dimethylarginine Dimethylaminohydrolase
Promotes Endothelial Repair After Vascular Injury
Hakuoh Konishi, MD, PHD, Karsten Sydow, MD, John P. Cooke, MD, PHD
Stanford, California
Objectives We sought to determine if a reduction in asymmetric dimethylarginine (ADMA) enhances endothelial regeneration.
Background Asymmetric dimethylarginine is an endogenous inhibitor of nitric oxide synthase (NOS). Increased plasma levels
of ADMA are associated with endothelial vasodilator dysfunction in patients with vascular disease or risk factors.
Asymmetric dimethylarginine is eliminated largely by the action of dimethylarginine dimethylaminohydrolase
(DDAH), which exists in 2 isoforms. Dimethylarginine dimethylaminohydrolase-1 transgenic (TG) mice manifest
increased DDAH activity, reduced plasma and tissue ADMA levels, increased nitric oxide synthesis, and reduced
systemic vascular resistance.
Methods The left femoral arteries of DDAH1 TG mice and wild-type (WT) mice were injured by a straight spring wire, and
regeneration of the endothelial cell (EC) monolayer was assessed. Endothelial sprouting was assayed with
growth factor-reduced Matrigel.
Results Regeneration of the EC monolayer was more complete 1 week after injury in TG mice (WT vs. TG: 40.0 6.5% vs.
61.2  6.4%, p  0.05). The number of CD45 positive cells at the injured sites was reduced by 62% in DDAH TG
mice (p  0.05). Four weeks after injury, the neointima area and intima/media ratio were attenuated in DDAH TG
mice (WT vs. TG: 0.049  0.050 mm2 vs. 0.031  0.060 mm2, 3.1  0.5 vs. 1.7  0.2, respectively, p  0.05).
Endothelial cell sprouting from vascular segments increased in TGmice (WT vs. TG: 24.3 3.9 vs. 39.0 2.2, p 0.05).
Conclusions We find for the first time an important role for DDAH in EC regeneration and in neointima formation. Strategies to
enhance DDAH expression or activity might be useful in restoring the endothelial monolayer and in treating vascular
disease. (J Am Coll Cardiol 2007;49:1099–105) © 2007 by the American College of Cardiology Foundation
















Aisruption of endothelium or its dysfunction promotes vas-
ular lesion formation (1,2). This is due in part to the loss of
ndothelial vasoprotective factors (such as nitric oxide [NO])
hat promote endothelial survival and proliferation, inhibit
ggregation of platelets, infiltration of leukocytes, and prolif-
ration of vascular smooth muscle cells (VSMCs) (3,4). The
asoprotective factor NO is derived from the metabolism of
-arginine by NO synthase (NOS). In 1992, Vallance et al. (5)
escribed an endogenous inhibitor of NOS, asymmetric di-
ethylarginine (ADMA), that inhibits NOS by competing
ith L-arginine for binding to the enzyme. The plasma level of
DMA is increased in patients with cardiovascular risk factors
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006, accepted October 9, 2006.ndmight contribute to the endothelial vasodilator dysfunction
bserved in these subjects (6–12).
The major route for ADMA degradation is by the enzyme
imethylarginine dimethylaminohydrolase (DDAH) (13,14).
wo isoforms of DDAH are known, with overlapping tissue
istribution (15). We have established a line of DDAH1
ransgenic mice in which the human DDAH1 gene is driven
y a beta-actin promoter, causing its overexpression in all
issues. These transgenic mice display increased tissue
DAH activity, reduced plasma ADMA levels, and in-
reased NO synthesis (16).
Because NO enhances endothelial cell (EC) migration
nd proliferation (17,18), we hypothesized that DDAH
verexpression would increase NO synthesis and thereby
romote re-endothelialization. To address these hypothe-
es, we used a mechanical vascular injury model in vivo as
ell as an ex vivo EC proliferation assay.
ethods
nimals. All experiments were conducted with 5- to
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termates, matched for age, gen-
der, and weight, were used as
control subjects (each group n 
25). The study was approved by
the Administrative Panel on
Laboratory Animal Care of
Stanford University. Translumi-
nal mechanical injury of the fem-
oral artery was induced as de-
scribed (19,20). Animals were
anesthetized with ketamine (80
mg/kg) and xylazine (16 mg/kg).
After incision and blunt dissec-
ion, the vascular segment to be injured was completely
xposed to direct visual inspection. A straight spring wire (7
m length, 0.38 mm diameter) was inserted in a retrograde
ashion through an exposed muscular branch artery into the
emoral artery. In all cases, when the spring wire was passed
nto the vessel, a very obvious distention of the vessel was
oticed. In addition, there was resistance to placement of
he wire in the femoral artery. After 1 min the wire was
emoved, and the proximal portion of the muscular branch
rtery was ligated with silk suture. To confirm that this
pproach fully denuded the endothelium from the femoral
rtery, 2 animals (1 WT and 1 DDAH mouse) were killed
mmediately after the procedure. By Evan’s blue staining,
he endothelium was completely removed from the area of
nterest in each animal.
Plasma ADMA concentrations were measured by
nzyme-linked immunosorbent assay (ELISA). The anti-
DMA antiserum used in this ELISA has low cross-
eactivity with related substances (21). The cross-reactivity
or symmetric dimethylarginine and L-arginine is 1.2% and
.02%, respectively. The analytical sensitivity is 0.05
mol/l. The coefficients of variation are 4.5% to 7.5%
intra-assay) and 8.3% to 10.3% (interassay). All measure-
ents were performed in duplicate, and mean values were
omputed.
egeneration of femoral artery endothelium. To quantify
ndothelial regeneration 1 week after vascular injury, we
njected 50 l of 5% Evan’s blue in saline via tail vein 10
in before subjects were killed (22). After perfusion fixation
ith 10% phosphate-buffered formalin (pH 7.0) for 5 min,
he arteries were removed and opened longitudinally and
laced on glass slides (n  8 for each group). The area of
enudation (stained by Evan’s blue) was quantified by light
icroscopy with Image J software (National Institutes of
ealth, Bethesda, Maryland). Re-endothelialization was
alculated by substracting the stained area from the original
rea of denudation and dividing by the original area of
enudation.
istology and morphometry. At 7 or 28 days after injury,
he femoral arteries were fixed by perfusion in 10%







EC  endothelial cell
NO  nitric oxide
NOS  NO synthase
TG  DDAH transgenic
mice
WT  wild-type micehysiological pressure via the left ventricle. The femoral nrteries were embedded in optimal cutting temperature
ompound and sectioned (10 m). We used hematoxylin-
osin (H&E) staining for overall morphology or elastica van
ieson’s staining to depict the internal elastic lamina and
he external elastic lamina (n  13 for each group). Seven
ays after injury, immunohistochemical staining was per-
ormed with anti-mouse CD45 antibody (clone 30-F11 BD
harmingen, San Diego, California; n  6 for each group)
o identify inflammatory cells. Inflammatory cell numbers
ere counted by light microscopy and expressed as the
verage number of cells/cross-section. Morphometric anal-
ses were carried out on femoral arteries harvested 28 days
fter injury (n  7 for each group). Arterial specimens were
nalyzed by light microscopy in a blinded fashion with
POT Advanced Version 3.4.2 software (Diagnostic In-
truments, Inc., Sterling Heights, Michigan).
C sprouting. To assess EC regenerative capacity, we used
n ex vivo aortic ring assay (23,24). Descending thoracic
ortae were isolated from wild-type and DDAH TG mice
each group n 4). Under a dissecting microscope, multiple
-mm-thick aortic rings were prepared. Rings were then
laced between 2 layers of growth factor-reduced Matrigel
BD Biosciences, San Jose, California) supplemented with
ulbecco’s Modified Eagle Medium (GIBCO, Carlsbad,
alifornia), 5% fetal bovine serum, 10 U/ml heparin, and
ascular endothelial growth factor (VEGF) 10 ng/ml (Life
echnologies, Gaithersburg, Maryland). One week after
mbedding the rings into Matrigel, number of sprouts were
uantified as previously described (23,24).
tatistical analysis. Statistical analysis was performed with
tatView 5.0 (SAS Institute, Cary, North Carolina). All
ata are given as mean  SEM. Comparisons between
roups were analyzed by unpaired Student t test. Statistical
ignificance was accepted at p  0.05.
esults
DAH overexpression accelerates endothelial regenera-
ion after vascular injury. As expected, plasma levels of
DMA were lower in DDAH TG mice compared with
ild-type mice at baseline (WT vs. TG: 0.94 0.06 mol/l
s. 0.68  0.05 mol/l, p  0.01) and after vascular injury
at 7 days after injury, WT vs. TG: 0.88  0.06 mol/l vs.
.57  0.04 mol/l; and at 28 days: 1.00  0.06 mol/l vs.
.60  0.03 mol/l; p  0.01).
Evan’s blue staining of femoral arteries harvested 7 days
fter injury revealed segments of the artery where endothe-
ial regeneration was incomplete (Fig. 1A). Endothelial
egeneration in DDAH TG mice was more complete (WT
s. TG: 40.0 6.5% vs. 61.2 6.4% of injured surface area
n  8], p  0.05) (Fig. 1B).
DAH overexpression reduces inflammatory infiltrate.
even days after injury, neointima and inflammatory infil-
rate was attenuated in the injured segment of femoral
rteries harvested from DDAH TG mice (Fig.2). The
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March 13, 2007:1099–105 ADMA, DDAH, and Endothelial RegenerationDAH TG mice (WT vs. TG: 46.3  8.2 vs. 17.5  6.5
ells/cross-section of injured segment [n  6], p  0.05).
eointima formation is reduced in DDAH TG mice
fter vascular injury. Neointima formation was quanti-
ated 28 days after injury (Fig. 3). The neointima area and
ntima/media ratio were significantly reduced in DDAH
G mice (WT vs. TG: 0.049  0.050 mm2 vs. 0.031 
.060 mm2, 3.1  0.5 vs. 1.7  0.2, respectively [n  7],
 0.05). There was no difference between the groups in
edial area.
Figure 1 Endothelial Regeneration Is Accelerated in DDAH TG
(A) Evans blue staining showed segments of each artery that have not recovered
(DDAH) transgenic (TG) mice is reduced compared with wild-type (WT) mice. (B) Qu
nally injured. *p  0.05 (n  8).
Figure 2 Neointima and Inflammation Is Reduced in DDAH TG M
(A) Hematoxylin-eosin staining and immunohistochemical staining with anti-CD45
sections of injured arteries from DDAH TG mice by comparison with those from WT
*p  0.05 (n  6). Abbreviations as in Figure 1.ndothelial sprouting is increased in DDAH TG
ice. Endothelial sprouting from aortic rings ex vivo re-
uires EC proliferation, migration, survival, and tube for-
ation. We examined the degree of endothelial sprouting 1
eek after embedding aortic rings into Matrigel. Typical
ndothelial sprouting in WT or DDAH TG mice is shown
Fig. 4A). Quantification of endothelial sprouting (Fig. 4B)
evealed that the number of sprouts in DDAH TG mice
ere significantly more extensive (WT vs. TG: 24.3  3.9
s. 39.0  2.2 sprouts/aortic ring [n  4], p  0.05).
elium. The stained (denuded) area in dimethylarginine dimethylaminohydrolase
ation of regenerated endothelium expressed as a percentage of the area origi-
dy revealed that neointima and inflammatory infiltrate were reduced in vascular
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DAH and endothelial regeneration. The salient obser-
ations of this study are that overexpression of DDAH and
educed plasma ADMA levels are associated with enhanced
ndothelial regeneration and suppression of inflammation
nd neointima formation after vascular injury. Aortic rings
rom DDAH transgenic mice manifest greater endothelial
prouting ex vivo. These observations might be explained by
he effect of DDAH to metabolize ADMA and thereby
ncrease tissue generation of NO.
Our results are consistent with earlier observations reveal-
ng a critical role for NO in EC regeneration (17,18). Nitric
xide is an endothelial survival factor, preventing apoptosis
17,18), supporting proliferation (25,26), and promoting
igration (10,27,28). Migration requires EC interaction
ith the matrix, which is enhanced by NO-induced expres-
ion of alphavbeta3 (16). This integrin is the ligand for the
xtracellular matrix protein Del-1, which participates in
ngiogenesis (29). Migration also requires the dissolution of
he extracellular matrix. Nitric oxide might enhance matrix
egradation by activation of matrix metalloproteinases or via
Figure 3 Neointima Formation Was Reduced in DDAH TG Mice
(A) Elastica van Gieson’s staining shows neointima formation after vascular injury
intima/media (I/M) ratios in DDAH TG mice were significantly less than that of WThe stimulation of basic fibroblast growth factor (bFGF), thich upregulates urokinase-type plasminogen activator
26). In addition, NO might influence endothelial prolifer-
tion via the endothelial mitogen, VEGF. Pharmacological
r genetic augmentation of NO production increases VEGF
xpression in cultured vascular cell (30,31). In cultured cells,
verexpression of DDAH increases VEGF expression
32,33).
DMA inhibits vasoprotective effects of NO. Endothe-
ial cells resurfacing an injured vessel express higher intra-
ellular levels of ADMA and have impaired endothelium-
ependent vasodilatation (34). Intriguingly, the severity of
he impairment in endothelium-dependent NO-mediated
asodilation is correlated with the amount of myointimal
yperplasia (35). Plasma levels of ADMA independently
redict subsequent adverse cardiovascular events in patients
ndergoing percutaneous coronary intervention (36). These
ndings are consistent with the role of NO to inhibit
SMC proliferation and migration (37,38). The impor-
ance of NO for vascular structure is shown by studies where
harmacological or genetic suppression of NOS accelerates
yointimal hyperplasia after vascular injury (39). By con-
ays After Injury
eointimal area and
 *p  0.05 (n  7). Abbreviations as in Figure 1.28 D
. (B) N
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March 13, 2007:1099–105 ADMA, DDAH, and Endothelial Regenerationyperplasia after balloon angioplasty (40–42). We have
reviously examined the effect of DDAH overexpression on
ardiac allograft vasculopathy (CAV). We have shown that
eterotopic cardiac transplantation into DDAH transgenic
ice is associated with a less severe form of CAV (43).
yointimal hyperplasia, inflammatory infiltrate, and in-
ammatory cytokines are reduced in the transplanted heart
f the transgenic animals (43), revealing the vasoprotective
ctions of NO in this model.
In addition to enhancing the action of endothelial NOS,
t is possible that DDAH overexpression increases the
ctivity of the inducible form of NOS (iNOS). After
ascular injury, iNOS expression is induced in VSMCs (44).
vidence suggests that the expression of iNOS under these
ircumstances could be vasoprotective by inhibiting platelet
dhesion (44) and reducing myointimal hyperplasia (45).
hus, NO produced by iNOS in the vascular smooth
uscle might compensate for the loss of endothelial NOS,
nd its activity might be enhanced in the DDAH transgenic
ouse.
DMA inhibits angiogenesis and vascular regeneration.
egments of aorta placed in Matrigel will give rise to
ndothelial sprouts. The magnitude of endothelial sprouting
Figure 4 One Week After Injury, Vascular Segments Were Emb
Reduced Matrigel, and the Number of Sprouting Micro
(A) Representative aortic rings showed increased endothelial sprouting in a vascu
by comparison with those from a WT mouse. (B) Quantification of endothelial spros dependent upon EC proliferation, migration, and sur- eival. In rings taken from hypercholesterolemic mice,
prouting is impaired (46). In hypercholesterolemic mice,
lasma ADMA levels are increased, and angiogenic re-
ponse to ischemia is reduced. This effect can be reversed by
xogenous L-arginine or can be mimicked in WT mice by
he NOS antagonist L-nitroarginine (47). In the current
tudy, DDAH1 overexpression enhanced endothelial
prouting from aortic segments. These studies indicate that
he local balance between the NOS inhibitor and the NOS
ubstrate can effect endothelial proliferation. Notably, the
ndothelial sprouts in these aortic segments seem to derive
argely from the adventitial surface of the aortic rings. It has
een recently shown that there is a distinct zone between
he media and adventitial layer of human arteries containing
ells with the antigenic and functional properties of endo-
helial progenitor cells (48). It is possible that these resident
rogenitor cells contribute to regeneration of the endothe-
ium in vivo.
tudy limitations and alternative interpretations. We
ave not excluded the possibility that DDAH expression
ncreased the contribution of circulating progenitor cells to
egeneration of the endothelium. In this regard, NO is
equired for the mobilization of bone marrow–derived
d in Growth Factor
els Were Quantified
ment from a DDAH TG mouse,
p  0.05 (n  4). Abbreviations as in Figure 1.edde
vess
lar seg
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ADMA, DDAH, and Endothelial Regeneration March 13, 2007:1099–105rix metalloproteinase (49). In humans, plasma ADMA
evels were correlated to the severity of coronary artery
isease and inversely correlated with the number of circu-
ating CD34/CD133 progenitor cells and colony form-
ng units (50). Accordingly, a reduction in ADMA levels
ight accelerate endothelial regeneration by promoting
obilization of bone-marrow derived ECs. In this study we
id not study the potential contribution of circulating or
esident endothelial progenitor cells to regeneration of the
ndothelial monolayer. Furthermore, we have not excluded
O-independent effects of DDAH overexpression. Re-
ently, evidence has been provided that overexpression of
DAH-2 in cultured ECs might increase the cellular
xpression of VEGF, perhaps in an NO-independent man-
er (33).
onclusions
o conclude, DDAH transgenic mice had lower plasma
evels of ADMA, the endogenous NOS inhibitor. After
ndothelial denudation and vascular injury, endothelial re-
eneration was accelerated in the DDAH1 transgenic mice.
his effect is due at least in part to an acceleration of
ndothelial proliferation, migration, and/or survival as
hown by ex vivo studies. Furthermore, overexpression of
DAH was associated with reduced myointimal hyperpla-
ia in the injured vessel. Strategies to enhance DDAH
xpression or activity might be useful in restoring the
ndothelial monolayer and treating vascular disease.
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